THRA and cancer: Mutant variants of TRHs, such as THRα‐V390A and THRα‐E350 K/P398S, act as dominant negative of the wild‐type THRs and might escape from these regulatory mechanisms, promoting cancer progression (Chan & Privalsky, 2006; Lin et al., 1997; Sinha et al., 2018).